Westwood Holdings Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Westwood Holdings Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,856	Closed	-$916K	–	494
2022 Q4	$916K	Sell	3,856 -4,940	-56%	-$1.05M	0.01%	359
2022 Q3	$1.76M	Sell	8,796 -7,477	-46%	-$1.43M	0.02%	276
2022 Q2	$2.37M	Sell	16,273 -107	-0.7%	-$15.2K	0.03%	276
2022 Q1	$2.67M	Sell	16,380 -1,676	-9%	-$255K	0.02%	285
2021 Q4	$3.06M	Buy	18,056 +6,928	+62%	+$1.29M	0.03%	268
2021 Q3	$2.1M	Sell	11,128 -169	-1%	-$31.7K	0.02%	285
2021 Q2	$1.92M	Buy	+11,297	New	+$1.65M	0.02%	294

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Westwood Holdings Group's ALNY Position: Q1 2023 in Review

Westwood Holdings Group sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2023, closing a stake of 3,856 shares — an estimated $916K sold.

Westwood Holdings Group first reported a position in ALNY in Q2 2021 and held it in 7 quarters. The position peaked at $3.06M in Q4 2021. 477 funds tracked by Wall St. Rank hold ALNY as of Q1 2023.

Westwood Holdings Group reported no remaining Alnylam Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Westwood Holdings Group sold 3,856 Alnylam Pharmaceuticals shares in Q1 2023, an estimated $916K.
Westwood Holdings Group first reported a position in Alnylam Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Westwood Holdings Group's Alnylam Pharmaceuticals position peaked at $3.06M in Q4 2021.
477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2023.

Based on Westwood Holdings Group's 13F filing for Q1 2023, filed 12 May 2023.